We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing our proprietary bile acid chemistry. Our product candidates have the potential to treat orphan and more prevalent diseases for which there currently are limited therapeutic solutions.


Farnesoid X Receptor (FXR)—a new hope for liver disease

FXR plays a key role in many processes in the liver.




Primary Biliary Cirrhosis (PBC)—a rare disease with widening impact

PBC is an autoimmune chronic liver disease that primarily occurs in women. The disease is marked by abnormal blood levels of the liver enzyme alkaline phosphatase (ALP) and patients with persistently elevated ALP are at significant risk of progressing to cirrhosis. Despite being relatively rare, PBC is the fifth most common cause of liver transplant in the United States.

Learn More


Nonalcoholic Steatohepatitis (NASH)—a highly prevalent chronic liver disease

NASH is one of the most common chronic liver diseases worldwide with no drugs currently approved for treatment. The prevalence of this disease has risen rapidly in close association with the adoption of Western diet and increasing obesity. It is initiated by excess fat buildup in the liver and can lead to cirrhosis and liver cancer. NASH is projected to become the leading reason for liver transplant in the next few years.

Learn More